Table 5.
Patients’ secondary outcomes for administration of iron supplementation
| Treated (n = 152) |
Not treated (n = 206) |
P-value | adjusted OR (95% CI) |
adjusted P-value |
|
| Male, n (%) | 75 (49) | 118 (57) | 0.14 | 0.85 (0.39-1.85) | 0.68 |
| Gestational age (weeks), median (IQR) | 33.0 (31.9-34.0) | 35.1 (34.6-35.6) | <0.001 | 0.21 (0.12-0.34) | <0.001 |
| SGA, n (%) | 42 (28) | 33 (16) | 0.008 | 4.92 (1.51-16.1) | 0.008 |
| Caesarian section, n (%) | 128 (84) | 141 (68) | 0.001 | 1.13 (0.40-3.19) | 0.82 |
| Twin birth, n (%) | 40 (26) | 44 (21) | 0.55 | 1.88 (0.74-4.79) | 0.19 |
| Placental abruption | 9 (5.9) | 5 (2.4) | 0.09 | 6.03 (0.89-40.8) | 0.07 |
| Maternal Hb before birth (g/dL), mean (SD) | 10.7 (1.5) | 11.1 (1.3) | 0.010 | 0.66 (0.50-0.88) | 0.005 |
| Laboratory data at birth | |||||
| Hb (g/dL), mean (SD) | 16.7 (2.3) | 17.0 (2.1) | 0.05 | 0.75 (0.60-0.93) | 0.01 |
| MCV (fL), mean (SD) | 110 (6.5) | 107 (5.4) | <0.001 | 0.99 (0.92-1.06) | 0.80 |
| MCHC (%), mean (SD) | 34.1 (1.1) | 34.3 (0.93) | 0.007 | 0.81 (0.55-1.19) | 0.29 |
| Ret (×104/μL), mean (SD) | 26.2 (7.3) | 24.3 (5.7) | 0.003 | 0.95 (0.89-1.01) | 0.12 |
| High intensity breastfeeding, n (%) | 65 (43) | 38 (18) | <0.001 | 0.48 (0.21-1.11) | 0.09 |
| Treatment for jaundice, n (%) | 123 (81) | 97 (47) | <0.001 | 0.80 (0.30-2.11) | 0.65 |
| Number of blood samplings, median (IQR) | |||||
| Large sampling | 7 (6-9) | 3 (1-5) | <0.001 | 1.70 (1.34-2.16) | <0.001 |
| Small sampling | 13.5 (10-21) | 9 (6-12) | <0.001 | 1.00 (0.93-1.08) | 0.95 |
| Days at the initiation of treatment (days), mean (SD) | 24.7 (7.3) | ||||
| Hb at the initiation of treatment (g/dL), mean (SD) | 12.7 (1.5) |
SGA, small for gestational age; Hb, hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; Ret, absolute reticulocyte count